Venom-immunotherapy in patients with clonal mast cell disorders.
A new study published in Allergy evaluated the efficacy and safety of venom-immunotherapy (VIT) in hymenoptera venom anaphylaxis (HVA) patients with clonal mast cell disorders (cMCD). This retrospective study was conducted among 46 patients with Vespula-venom allergy who had experienced severe HVA. Among these, 32 were cMCD – 22 with systemic mastocytosis (SM) and 10 with monoclonal mast cell activation syndrome (MMAS), and 14 were controls. There were no differences between cMCD patients
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies